The collaboration aims to advance novel treatments for geographic atrophy patients using artificial intelligence. Credit: salvatore ventura on Unsplash.

Swiss company RetinAI Medical has collaborated with German pharmaceutical firm Boehringer Ingelheim to leverage artificial intelligence (AI) to advance novel treatments for geographic atrophy (GA) patients.

The companies aim to improve GA patients’ outcomes by combining RetinAl’s Discovery platform and AI tools with the retinal diseases research of Boehringer Ingelheim.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Used for identifying new biomarkers, RetinAI’s AI tools will be tested as they analyse Boehringer Ingelheim’s imaging datasets obtained from clinical trials and real-world evidence.

This will assist in identifying both additional new biomarkers and predictors of disease progression.

RetinAI stated that combining advanced digital technologies with AI could help expedite the development of new treatments, enabling earlier diagnosis of diseases.

This will contribute to Boehringer Ingelheim’s goal of preventing sight loss and blindness caused by retinal diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

RetinAI CEO Dr Carlos Ciller said: “RetinAI is excited to embark on this very important collaboration with Boehringer Ingelheim, a leader in the development of innovative, more precise treatments and application of digital technologies in retinal diseases.

“Our Discovery platform and novel AI tools in GA accelerate research and provide robust disease insights.

“We are confident that this collaboration with Boehringer Ingelheim can pave the way to novel treatments that are better tailored to a patient’s disease, to transform the lives of people living with retinal diseases.”